Byondis and Medac link up to commercialise trastuzumab duoca

Byondis and Medac have entered into a license and collaboration agreement for form of targeted chemotherapy - News - PharmaTimes

Related Keywords

United Kingdom , Marco Timmers , Jacques Lemmens , European Medicine Agency , Regulatory Agency , European Medicine , Chairman Jacques , Byondis , Redac , Trastuzumab Duocarmazine ,